Dr. Azza Gadir currently serves as the Director of R+D at Seed Health, a venture-backed microbial sciences company that accelerates breakthrough science into live biotherapeutics and innovations for consumer health under a unique foundry model. Each portfolio venture is built on its own proprietary platform to target pervasive, unmet medical needs for which bacteria may become or replace the primary standard of care. The current pipeline includes interventions for infectious disease, allergy, and inflammatory conditions across various body sites and windows of development. Dr. Gadir oversees Seed Health’s pre-clinical research, clinical trials, regulatory, academic collaborations, and IP acquisition.

After completing her PhD in immunology from University College London at 26, Dr. Gadir completed her postdoctoral training in the laboratory of Dr. Talal Chatila at Harvard Medical School/Boston Children’s Hospital, where her published research in journals such as Nature Medicine focused on the immunological mechanisms that underlie the role of the gut microbiome in conferring protection to diseases early in life. For this work, she holds issued and pending patents and has collaborated with industry partners to accelerate the discovery of microbiome-related immunotherapies for food allergy.

Dr. Gadir grew up in London and received an MSc in the Immunology of Infectious Diseases from the London School of Hygiene and Tropical Medicine. She has appeared on podcasts and been featured in press including Digital Health Today, Lemon Water, and DubLab.